AnaptysBio, Inc. (ANAB) vs Ultragenyx Pharmaceutical Inc. (RARE)
A side-by-side comparison of AnaptysBio, Inc. and Ultragenyx Pharmaceutical Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ANAB
AnaptysBio, Inc.
$48.22HealthcareDelayed quote: Oct 6, 2026, 12:25 PM EDT
RARE
Ultragenyx Pharmaceutical Inc.
$14.57HealthcareDelayed quote: Oct 6, 2026, 12:25 PM EDT
Total return — ANAB vs RARE
growth of $100 · dividends reinvested · last 10yANAB +334.2% (+15.8%/yr)RARE -78.9% (-14.4%/yr)ANAB compounded faster over this window
Log scale — wide-divergence pair
ANAB RARE
ANAB vs RARE: by the numbers
- •RARE is the larger company ($1.43B vs $1.43B market cap).
- •ANAB is profitable (82.37% net margin) while RARE runs a net loss (-81.79%).
- •ANAB grew revenue faster over the past five years (18.60% vs 14.81% CAGR).
Metrics side by side
Valuation
| Metric | ANAB | RARE |
|---|---|---|
| P/E ratio | 8.98 | N/A |
| P/S ratio | 6.01 | 2.00 |
| P/B ratio | 134.88 | N/A |
| EV / EBITDA | 11.52 | N/A |
| FCF yield | 1.26% | N/A |
Profitability
| Metric | ANAB | RARE |
|---|---|---|
| Gross margin | 98.97% | 83.12% |
| Operating margin | 20.42% | -73.77% |
| Net margin | 82.37% | -81.79% |
| ROE | 1849.06% | N/A |
| ROIC | 47.55% | -53.48% |
Growth (annualized)
| Metric | ANAB | RARE |
|---|---|---|
| Revenue CAGR (5Y) | 18.60% | 14.81% |
| FCF CAGR (5Y) | 27.41% | N/A |
| Total return CAGR (5Y) | 21.54% | -30.14% |
Frequently asked
- Which has grown faster, ANAB or RARE?
- Over the past five years, ANAB grew revenue faster — ANAB at a 18.60% CAGR versus RARE at 14.81%.
- Is ANAB or RARE more profitable?
- ANAB runs the higher net margin — ANAB at 82.37% versus RARE at -81.79%.
- How have ANAB and RARE total returns compared?
- Over the past 5 years, ANAB delivered 21.54% and RARE delivered -30.14% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
AnaptysBio P/E ratioAnaptysBio ROEUltragenyx Pharmaceutical ROEAnaptysBio operating marginUltragenyx Pharmaceutical operating marginAnaptysBio revenue growthUltragenyx Pharmaceutical revenue growthAnaptysBio free cash flowUltragenyx Pharmaceutical free cash flow
AnaptysBio & Ultragenyx Pharmaceutical appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.